104 related articles for article (PubMed ID: 12207573)
1. Ageing blunts the effects of nitric oxide on myocardial O2 consumption.
Weiss HR; Lazar MJ; Tse J; Scholz PM
Clin Exp Pharmacol Physiol; 2002 Oct; 29(10):924-30. PubMed ID: 12207573
[TBL] [Abstract][Full Text] [Related]
2. Chronic nitric oxide synthase blockade desensitizes the heart to the negative metabolic effects of nitric oxide.
Davidov T; Weiss HR; Tse J; Scholz PM
Life Sci; 2006 Sep; 79(17):1674-80. PubMed ID: 16831448
[TBL] [Abstract][Full Text] [Related]
3. Reduced myocardial cyclic GMP increases myocardial O2 consumption in control but not renal hypertension-induced cardiac hypertrophy.
Sadoff JD; Scholz PM; Tse J; Weiss HR
Cardiovasc Res; 1997 Dec; 36(3):453-9. PubMed ID: 9534866
[TBL] [Abstract][Full Text] [Related]
4. Negative metabolic effects of cyclic GMP are altered in renal hypertension induced cardiac hypertrophy.
Rabindranauth P; Naim KL; Scholz PM; Tse J; Sadoff JD; Weiss HR
Basic Res Cardiol; 1997 Feb; 92(1):8-16. PubMed ID: 9062647
[TBL] [Abstract][Full Text] [Related]
5. Altered relationship between cyclic GMP and myocardial O2 consumption in renal hypertension-induced cardiac hypertrophy.
Rabindranauth P; Scholz PM; Tse J; Naim KL; Weiss HR
Res Exp Med (Berl); 1998 Jul; 198(1):11-21. PubMed ID: 9706666
[TBL] [Abstract][Full Text] [Related]
6. Ethanol-induced reduction in myocardial oxygen consumption can be attenuated by inhibiting guanylyl cyclase.
Lazar MJ; Patel K; Scholz PM; Weiss HR
J Cardiovasc Pharmacol; 2001 Oct; 38(4):512-9. PubMed ID: 11588521
[TBL] [Abstract][Full Text] [Related]
7. Increased O2 consumption and positive inotropy caused by cyclic GMP reduction are not altered after L-type calcium channel blockade.
Leone RJ; Naim KL; Scholz PM; Weiss HR
Pharmacology; 1998 Jan; 56(1):37-45. PubMed ID: 9467186
[TBL] [Abstract][Full Text] [Related]
8. Relationship between cGMP and myocardial O2 consumption is altered in T4-induced cardiac hypertrophy.
Weiss HR; Rodriguez E; Tse J
Am J Physiol; 1995 Feb; 268(2 Pt 2):H686-91. PubMed ID: 7864195
[TBL] [Abstract][Full Text] [Related]
9. Cyclic GMP attenuates cyclic AMP-stimulated inotropy and oxygen consumption in control and hypertrophic hearts.
Leone RJ; Straznicka M; Scholz PM; Weiss HR
Basic Res Cardiol; 2000 Feb; 95(1):28-38. PubMed ID: 10752543
[TBL] [Abstract][Full Text] [Related]
10. Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts.
Weiss HR; Rodriguez E; Tse J; Scholz PM
Clin Exp Pharmacol Physiol; 1994 Aug; 21(8):607-14. PubMed ID: 7813120
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of the nitric oxide-cGMP pathway in aged myocardium: physiological response to l-arginine.
Zieman SJ; Gerstenblith G; Lakatta EG; Rosas GO; Vandegaer K; Ricker KM; Hare JM
Circ Res; 2001 Jan; 88(1):97-102. PubMed ID: 11139480
[TBL] [Abstract][Full Text] [Related]
12. Increases in myocardial cyclic GMP attenuate contractile delay in myocardial stunning.
Huang MW; Scholz PM; Weiss HR
Can J Physiol Pharmacol; 2002 Aug; 80(8):804-10. PubMed ID: 12269791
[TBL] [Abstract][Full Text] [Related]
13. Myocardial effects of cyclic AMP phosphodiesterase inhibition are dampened in thyroxine-induced cardiac hypertrophy.
Straznicka M; Leone RJ; Scholz PM; Weiss HR
J Surg Res; 1998 Apr; 76(1):61-6. PubMed ID: 9695741
[TBL] [Abstract][Full Text] [Related]
14. Basal muscarinic activity does not impede beta-adrenergic activation in rabbit hearts in controls or thyroxine-induced cardiac hypertrophy.
Naim KL; Rabindranauth P; Scholz PM; Tse J; Weiss HR
J Cardiovasc Pharmacol; 1997 Oct; 30(4):405-11. PubMed ID: 9335397
[TBL] [Abstract][Full Text] [Related]
15. Negative metabolic and coronary flow effects of decreases in cAMP and increases in cGMP in control and renal hypertensive rabbit hearts.
Rodriguez R; Molino B; Weiss HR; Scholz PM
J Appl Physiol (1985); 2004 Jul; 97(1):439-45. PubMed ID: 14990553
[TBL] [Abstract][Full Text] [Related]
16. Reduction in the level of cardiac cyclic GMP worsens contractile delay in myocardial stunning.
Patel KN; Weiss HR; Scholz PM
J Surg Res; 2000 Jul; 92(1):114-9. PubMed ID: 10864491
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of beta- but not alpha 1-mediated adrenergic responses in isolated hearts and cardiomyocytes by nitric oxide and 8-bromo cyclic GMP.
Ebihara Y; Karmazyn M
Cardiovasc Res; 1996 Sep; 32(3):622-9. PubMed ID: 8881523
[TBL] [Abstract][Full Text] [Related]
18. cGMP level that reduces cardiac myocyte O2 consumption is altered in renal hypertension.
Straznicka M; Gong G; Tse J; Scholz PM; Weiss HR
Am J Physiol; 1997 Oct; 273(4):H1949-55. PubMed ID: 9362265
[TBL] [Abstract][Full Text] [Related]
19. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro. Implications for the development of heart failure.
Xie YW; Shen W; Zhao G; Xu X; Wolin MS; Hintze TH
Circ Res; 1996 Sep; 79(3):381-7. PubMed ID: 8781471
[TBL] [Abstract][Full Text] [Related]
20. Effect of cyclic GMP reduction on regional myocardial mechanics and metabolism in experimental left ventricular hypertrophy.
Guo X; Kedem J; Weiss HR; Tse J; Roitstein A; Scholz PM
J Cardiovasc Pharmacol; 1996 Mar; 27(3):392-400. PubMed ID: 8907801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
